Intercept loses Ocaliva FDA full approval bid in rare liver disease
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease treatment.
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease treatment.
A GlobalData analyst has warned that Trump's second term could see major changes in US healthcare, and RFK could rock the boat.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
DeepMind Nobel Prize winner says AI will have “electricity” type of impact
Zentiva voices UWWTD concerns as EU grants approval
FDA approves Journey Medical’s rosacea treatment Emrosi
NCCN visits Vietnam in continued cancer care collaboration